MDM2 and melanoma: In our previous investigation of SNP309 in a hospital-based cohort of nearly 1000 melanoma patients, the MDM2 SNP309 allele did not have a statistically significant effect on disease recurrence or melanoma death; however, in adjusted analysis for covariates, we did observe a trend suggestive of a protective effect for the SNP309*G-allele in relation to mortality: HRhet = 0.74, 95% CI 0.47–1.15, and HRGG= 0.59, 95% CI 0.32–1.10 [13].